



**MedStar Family  
Choice**

5233 King Ave., Ste. 400  
Baltimore, MD 21237  
800-905-1722  
MedStarFamilyChoice.com

### **Maryland Medicaid to Cover Cell and Gene Therapy for Sickle Cell Disease**

Starting January 1, 2026, Maryland Medicaid will cover FDA-approved cell and gene therapies for sickle cell disease through the CMS Cell and Gene Therapy (CGT) Access Model.

Maryland Medicaid will cover the full care journey for eligible participants, including evaluation, apheresis, infusion, recovery, and long-term follow-up at authorized treatment centers.

Maryland Medicaid will cover CASGEVY and LYFGENIA for eligible participants through the CMS Cell and Gene Therapy Access Model.

Providers should discuss this option with eligible patients and refer them for evaluation as appropriate. Visit the new Maryland Medicaid cell and gene therapy webpage for clinical criteria and additional resources <https://bit.ly/49hMXTt>